Scholar Rock Reports Q1 Losses, Resubmits SMA Drug BLA with Sept 30 PDUFA Date After Prior CRL
summarizeSummary
Scholar Rock Holding Corp reported Q1 2026 financial results, including a net loss of $105.51 million and EPS of ($0.83), alongside a comprehensive loss of $104.91 million. Crucially, the company announced the resubmission of its Biologics License Application (BLA) for apitegromab, its lead SMA drug, following a prior Complete Response Letter (CRL). A PDUFA date has been set for September 30, 2026. This regulatory update is significant, as the previous 10-K (March 3, 2026) disclosed the receipt of a CRL for apitegromab, which had delayed commercialization. The resubmission and PDUFA date indicate progress towards potential market approval. The setting of a PDUFA date for apitegromab is a major catalyst for Scholar Rock, providing a clear timeline for a potential U.S. launch of its key drug. This development significantly de-risks the regulatory pathway for apitegromab, which is critical for the company's future revenue generation. Traders will closely monitor the FDA's decision on apitegromab by the September 30 PDUFA date, as well as further updates on the Phase 2 FSHD and SRK-439 Phase 1 topline data expected in the second half of 2026.
At the time of this announcement, SRRK was trading at $46.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $27.07 to $51.63. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.